Faster, Cost-Effective, Reliable: Drug Target Humanized Mice for IND-Enabling Toxicology

Toxicology studies are a cornerstone of drug development. They inform clinical dose selection, identify potential safety risks, and are essential for meeting regulatory requirements in IND and NDA/BLA submissions.

Adapted from "Rang, H.P. 2006. Drug discovery and development. Elsevier. London"

Traditionally, non-human primates (NHPs) have been widely used in preclinical toxicology. However, growing ethical concerns, high costs, and lengthy study timelines have prompted regulators and industry leaders to explore alternatives. On April 10, 2025, the FDA announced plans to reduce reliance on NHPs in toxicology studies, while recognizing drug-target humanized mouse models as valid alternatives. Reflecting this shift, the industry is increasingly adopting humanized mouse models for IND-enabling toxicology studies.

Why Humanized Mice?

Humanized mouse models are genetically engineered to express human-specific genes, allowing researchers to test drug candidates directly against their intended human targets. Compared with NHPs, they offer multiple advantages:

• Preserve human target specificity and mechanism of action
• >50% cost savings and faster study timelines
• Lower test material requirements, due to the smaller body size of mice

By addressing both scientific and practical challenges, humanized mice provide a more efficient and human-relevant platform for toxicology evaluation.

Biocytogen’s Humanized Mouse Models for Toxicology

At Biocytogen, we have pioneered the development and application of drug-target humanized mouse models for preclinical safety studies. Our models have been widely validated and adopted by pharmaceutical companies worldwide, contributing directly to regulatory filings and approvals:

• Supported FDA/NMPA/TGA IND approvals for >20 drug candidates.
• 2 drugs received BLA approval from the NMPA.
• Successfully applied in general toxicity and DART (Developmental and Reproductive Toxicology) studies.
• Verified across diverse drug types, including monoclonal antibodies, bispecific antibodies, and ADCs.

▷ IND-Ready Support

Our experience and infrastructure ensure smooth integration of humanized mouse data into regulatory submissions:

• Proven experience working with major safety assessment centers
• Regulatory-ready product data packages, directly usable as IND supplementary files
• Comprehensive datasets supporting long-term and reproductive toxicity studies

▷ Cutting-Edge Technology

Biocytogen’s technical foundation ensures quality, consistency, and reliability in toxicology research:

• 10+ years of gene editing expertise
• Extensive model validation covering target expression, function, and drug binding
• Proprietary IVF technology, enabling synchronized large cohorts with body weight variation of less than 3g

Case Study1: IL4/IL4Ra Humanized Mice (B-hIL4/hIL4Rα) in Asthma Drug Evaluation

A recent example highlights the power of Biocytogen's humanized models in real-world drug development.

Indication: Asthma

Candidate: LQ036, an inhalable nanobody blocking IL-4Rα, a validated asthma pathway (Zhu et al. 2024)

Study Design: 

• GLP-compliant repeat-dose toxicity study in B-hIL4/hIL4Rα humanized mice
• Efficacy study on OVA-induced acute allergic inflammation in B-hIL4/hIL4Rα humanized mice
• Pharmacokinetics and tissue biodistribution of LQ036 in B-hIL4/hIL4Rα humanized mice. 

Findings on LQ036 Toxicity:

• NOAEL (No Observed Adverse Effect Level) established at 20.9 mg/kg
• No significant toxicological changes in clinical chemistry
• Key cytokines (IL-2, IL-6, IL-10, IFN-γ, TNF-α) remained normal
• Key immune markers (IgA, IgG, C3, CIC, T cells, CD4+, CD8+, CD4+/CD8+ ratio) remained normal
• Low immunogenicity, with anti-drug antibodies detected in only a few animals

Clinical Status: LQ036 has advanced into Phase IIa clinical trials in China

A novel inhalable nanobody targeting IL-4Rα for the treatment of asthma (Source: Zhu et al. 2024)

Toxicology of LQ036 (Source: Zhu et al. 2024)

Case Study 2: CD16 Humanized Mice in Autoimmune Drug Evaluation

Indication: Autoantibody-mediated disorders, modeled in immune thrombocytopenic purpura (ITP)

Candidate: GMA161, a humanized anti-CD16A antibody designed to block FcγRIII (CD16)–mediated clearance of platelets by autoantibodies. 

Study Design: Repeat-dose toxicity study using CD16 humanized mice.

Findings:

• Hypersensitivity-like reactions within 15–30 minutes after the second dose.
• Modest, transient cytokine elevations (e.g., IL-6, IL-12), below levels associated with cytokine release syndrome.
• Dose-dependent anti-drug antibody formation.
• Minimal to mild bone marrow hypercellularity.

Repeated-dose toxicity of GMA161 in CD16 humanized mice (Source: Flaherty et al. 2012)

Looking Ahead

Humanized mouse models are gaining traction in regulatory toxicology. With FDA endorsement and growing adoption across the biopharmaceutical industry, they are emerging as a cost-effective and scientifically robust alternative to traditional NHP studies.

At Biocytogen, we are proud to be at the forefront of this shift. By leveraging advanced genetic engineering, validated model systems, and regulatory expertise, we help partners accelerate the path from preclinical research to clinical success.

Contact us today to streamline your IND-enabling toxicology programs with Biocytogen!

FAQ on Humanized Mouse Models in Toxicology